ZCZhiwen Cheng

Zhiwen Cheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhiwen Cheng has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Buchun Jiang

    Department of Nephrology, The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China

    1 shared publication
  • Dongjie Wang

    Department of Nephrology, The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China

    1 shared publication
  • Fei Liu

    Department of Nephrology, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China

    1 shared publication
  • Haidong Fu

    Department of Nephrology, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China

    1 shared publication
  • Jianhua Mao

    Department of Nephrology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children’s Regional Medical Center, Hangzhou, China

    1 shared publication
  • Jingjing Wang

    Department of Nephrology, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China

    1 shared publication

Latest Publications

  • Open Access

    Unveiling the podocyte-protective effect of sodium-glucose cotransporter-2 inhibitors

    by Buchun Jiang, Zhiwen Cheng, Dongjie Wang, Fei Liu, Jingjing Wang, Haidong Fu, Jianhua Mao

    The renoprotective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in both diabetic and nondiabetic nephropathy are widely recognized due to results from randomized controlled trials notably the DAPA-CKD and EMPA-KIDNEY trials. Research exploring the mechanisms of renoprotection indicates that SGLT2 inhibitors exert protective effects on podocytes by enhancing autophagy and stabilizing the structure of podocytes and basement membranes. Furthermore, reductions in lipotoxicity, oxidative stress, and inflammation have been confirmed with SGLT2 inhibitor treatment. Recent clinical studies have also begun to explore the effects of SGLT2 inhibitors on nondiabetic podocytopathies, such as focal segmental glomerulosclerosis. In this review, we summarize clinical and laboratory studies that focus on the podocyte-protective effects of SGLT2 inhibitors, exploring the potential for broader applications of this novel therapeutic agent in kidney disease.